<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705978</url>
  </required_header>
  <id_info>
    <org_study_id>S245.4.009</org_study_id>
    <nct_id>NCT00705978</nct_id>
  </id_info>
  <brief_title>Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis</brief_title>
  <official_title>A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Datamap</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide efficacy data for Creon 40,000 in CP subjects as well as long-term
      safety data. During the long-term treatment with Creon 40,000 nutritional parameters will be
      assessed and correlated with CFA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CFA from baseline to the end of double blind treatment</measure>
    <time_frame>7 days after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNA, stool fat, stool weight, nutritional, clinical symptomatology, SF-36, BMI</measure>
    <time_frame>7 days after baseline, and end of open-label period (1 year of open label treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pancreatin</intervention_name>
    <description>Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Pancreatic exocrine insufficiency has to be proven (in medical history) by a
             pancreatic function test

          -  Chronic pancreatitis has to be proven (in medical history) by CT, ERCP, plain film
             with pancreatic calcifications, ultrasonography (calcifications,duct dilatation) and
             /or histology

          -  Females must be non-lactating and either be of non-childbearing potential or if of
             childbearing potential, agree to practice effective barrier contraceptive methods, use
             an intrauterine device (IUD) or use birth control pills or equivalent injectable
             contraceptive. The subject must have been practicing the selected method of birth
             control for at least 3 months prior to Visit 1 (Day -14).

          -  Subjects with a pathological stool fat during run in period (&gt; 10g/24 h)

        Exclusion Criteria

          -  Ileus or acute abdomen

          -  Any type of malignancy involving the digestive tract in the last 5 years

          -  Presence of pseudo pancreatic cysts &gt;= 4 cm

          -  Current excessive intake of alcohol or drug abuse

          -  Hypersensitivity vs porcine proteins / pancreatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenter Krause, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Products</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45389</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45396</name>
      <address>
        <city>Bhopal</city>
        <zip>462 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45390</name>
      <address>
        <city>Chennai</city>
        <zip>600096</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54382</name>
      <address>
        <city>Cochin</city>
        <zip>682304</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45391</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45388</name>
      <address>
        <city>Jaipur</city>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45387</name>
      <address>
        <city>Kolkatta</city>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45383</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45382</name>
      <address>
        <city>Pune</city>
        <zip>411 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45395</name>
      <address>
        <city>Pune</city>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45393</name>
      <address>
        <city>Trivandrum</city>
        <zip>695607</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>August 16, 2011</last_update_submitted>
  <last_update_submitted_qc>August 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gregor Eibes, Clinical Trial Manager</name_title>
    <organization>Abbott Products</organization>
  </responsible_party>
  <keyword>Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

